Маркери запалення до і після аортокоронарного шунтування та ефективність статинів

О.Й. Жарінов, О.А. Єпанчінцева, І.В. Шклянка, А.І. Курченко, Б.М. Тодуров

Література

1. Gusev DE, Ponomar EG. The role of C-reactive protein and other markers of the acute phase of inflammation in atherosclerosis. Clinical medicine. 2006;5:25-30. (in Rus.).
2. Zykov MV., Barbarash OL., Karetnikova VN., Kashtalan VV. The use of biomarkers - cytokines in the diagnosis and prognosis of myocardial infarction: Methodological recommendations. Kemerovo, 2012:7-16. (in Rus.).
3. Karpov YuA., Sorokin EV. Atherosclerosis and inflammation factors: non-lipid mechanisms of statins action. Rus. Med. J. 2001;9(10):5-9. (in Rus.).
4. Mirolyubova OA, Dobrodeeva LK, Averina M, et al. The role of cytokines and apoptosis in the development of post-perfusion syndrome after open-heart surgery with artificial circulation.Kardiologiia. 2001;41(1):67-69. (in Rus.).
5. Nasonov EL, Pashokova EV, Aleksandrova EN. C-reactive protein - marker of inflammation in atherosclerosis (new data). Kardiologiia. 2002;7:53-62.
6. Naumov VG, Sumorokov AB, Ezhov MV, et al. The indices of chronic inflammation in patients with ischemic heart disease with the development of restenosis in the coronary stent. Kardiologiia. 2005;1:14-18. (in Rus.).
7. Shreyder EV, Shakhnovich RM, Kaznacheeva EI, et al. Prognostic value of inflammatory markers and NT-proBNP in various treatment options for patients with acute coronary syndrome. Kardiologicheskij Vestnik. 2008.(III, 2):44-53. (in Rus.).
8. Antoniades C, Demosthenous M, Reilly S, et al. Myocardial Redox State Predicts In-Hospital Clinical Outcome After Cardiac Surgery: Effects of Short-Term Pre-Operative Statin Treatment. J Amer Coll Cardiology. 2012;59(1):71-73.
9. Ascione R, Lloyd CT, Underwood MJ, et al. Inflammatory response after coronary revascularisation with or without cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1198-1204.
10. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National cholesterol educational program goal versus "usual" care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation Study(GREACE). Cur Med Res Opin. 2002;18:220-228.
11. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-48490.
12. Brull D. J, Sanders J, Rumley A, et al. Statin therapy and the acute in flammatoryresponse after coronary artery bypass grafting. Am J Cardiol. 2001;88:431-433.
13. Casadei B, et al. Perioperative statin treatment in cardiac surgery for the prevention of atrial fibrillation and perioperative myocardial damage: the Statin Therapy in Cardiac Surgery(STICS) trial. ESC Congress. Hotline. 2014;2.
14. Chello M, Anselmi A, Spadaccio C, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann Thorac Surg. 2007;83:1374-1380.
15. Chello M, Mastroroberto P, Patti G, et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart. 2003;89:538-543.
16. Christenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovasc Surg. 2001;9:33-43.
17. Collard CD, Body SC, Shernan SK, et al. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2006;132:392-400.
18. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000;86:1128-1130.
19. Entman ML, Smith WC. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc. Res. 2010;28:1301-1311.
20. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541-2619.
21. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know. Eur J Cardiothorac. 2005;28:569-575.
22. Frostegard J, Bennet A.M, Wiman B, et al. Association of ФНП-alpha serum levels and ФНПA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis. 2006;187:408-414.
23. Gerola LR, Oliveira SA, Moreira LFP, et al. Blood cardioplegia with warm reperfusion versus intermittent aortic crossclamping in myocardial revascularization: randomized controlled trial. J Thorac Cardiovasc Surg. 1993;106:491-496.
24. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000;21:1152-1158.
25. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 2004;108:626-635.
26. Klein DJ, Briet F, Nisenbaum R, et al. Endotoxemia related to cardiopulmonary bypass is associated with increased risk of infection after cardiac surgery: a prospective observational study. Crit Care. 2011;15:69.
27. Krivoy N, Adler Z, Saloma R, et al. Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol. 2008;13(4):171-174.
28. Laufs U, Adam Oliver. Acute effects of statins. J Am Coll Cardiol. 2012;59(1):71-73.
29. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:715-720.
30. Luesher TF, Vanhoutte PM. The Endothelium: modulator of cardiovascular function. Boca Raton. 2000:1-228.
31. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006;97:55-60.
32. Martakova L, Olejarova I, Danova K, et al. Cytokine levels in patients with a very low left ventricular ejection fraction after open heart surgery. Bratisl Lek Listy. 2001;102(12):548-551.
33. Menasché P. The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg. 2001;72:2260-2266.
34. Minxin W. Kuukasjärvi P. Cytokine responses in low-risk coronary artery bypass surgery. Intern J Angiology. 2001;10(1):27-30.
35. Mitchell LB, Exner DV, Wyse DG, et al. Prophylacticoral amiodarone for the prevention of arrhythmias that begin early after revascularization, valve replacement, or repair. JAMA. 2005;294:3093-3100.
36. Moyer CF, Sajuthi D, Tulli H, Williams JK. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Amer. J. Pathology. 1991;138:951-960.
37. Nader ND, Javadzadegan H, Nezami N, et al. High-sensitivity C-reactive protein(hs-CRP) and tumor necrotizing factor-alpha(TNF-alpha) after on- and off- pump coronary artery bypass grafting. HSR Proc. Intensive Care Cardiovasc. Anesth. 2010;2(1):27-33.
38. Ohashi Y, Kawashima S, Mori T, et al. Soluble CD40 ligand and interleukin- 6 in the coronary circulation after acute myocardial infarction. Intern J Cardiol. 2006;112(1):52-58.
39. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology. 2007;107:117-121.
40. Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation. 2004;110:45-49.
41. Patti G, Chello M, Candura D, et al. Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3. Circulation. 2006;114:145-1461.
42. Pinon P, Kaski JC. Inflammation, atherosclerosis and cardiovas-cular disease risk. Rev Esp Cardiol. 2006;59:247-258.
43. Pim van der Harst, Voors AA, Volbeda M, et al. Usefulness of preoperative c- reactive protein and soluble intercellular adhesion molecule 1 for redicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol. 2006;97:1697-1701.
44. Powell BD, Bybee KA, Valeti U, et al. Influence of preoperative lipid-lowering therapy on postoperative outcome in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;99:785-789.
45. Preeshagul I, Gharbaran R, Kyung H.J, et al. Potential biomarkers for predicting outcomes in CABG cardiothoracic surgeries. J Cardiothoracic Surgery. 2013;8:176.
46. Rakhit RD, Seiler C, Wustmann К, et al. Tumor necrosis factor and interleukin-6 release during primary percutaneous coronary intervention for acute myocardial infarction is related to coronary collateral flow. Coron Artery Dis. 2005;16(3):147-152.
47. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22(PROVE IT-TIMI 22) Investigators. C- reactive protein levels and outcomes after statin therapy. New Engl J Med. 2005;352(1):20-28.
48. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med. 1997;336:973-979.
49. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45(10):1644-1648.
50. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844.
51. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med. 2008;359:2195-2207.
52. Sacks FM, Pfeffer MA, Moye LA, et al. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med. 1996;355:1001-1009.
53. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenouse-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Investigartors. New Engl J Med. 1997;336:153-162.
54. Tsuyuki RT. Revascularization in patients with heart failure. CMAJ. 2006;175(4):361-365.
55. Tuzcu EM, Nissen SE, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering(REVERSAL) Investigators. New Engl J Med. 2005;352(1):29-38.
56. Wan S, DeSmet JM, Barvais L, et al. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2006;112:806-811.
57. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 2007;112:676-692.
58. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21:1574-1583.
59. Zych B, Pacholewicz J, Farmas A, et al. Operacje kardiochirurgiczne przetoczenia krwi i środków krwiopochodnych. Kardichir Torakochir Pol 2004;1:31-40.

Значення реваскуляризації та прихильності до терапії в розвитку серцево-судинних ускладнень при тривалому спостереженні у хворих з інфарктом міокарда правого шлуночка на тлі інфаркту міокарда із зубцем Q задньої стінки лівого шлуночка

В.Й. Целуйко, Т.А. Лозова, В.П. Желєзний, О.С. Сасюк

Література

1. Kovalenko VM, Kornatsky VМ. Diseases of the circulatory system as a medical and social and socio-political problem. Analytical and statistical textbook. Кyiv, 2014. 280 p. (in Ukr.).
2. Briffa T, Hickling S, Knuiman M. et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth MONICA cohort, 1984-2005. BMJ. 2009;26:338-346.
3. Desai NR, Choudhry NK. Impediments to adherence to post myocardial infarction medications. Curr Cardiol Rep. 2013;15(1):322.
4. Din J, Janssen C, Robinson SD. et al. Non-adherence with clopidogrel after coronary stenting is associated with increased mortality and myocardial infarction. JACC. 2013;61:10-16.
5. Erne P, Schoenenberger AW, Burckhardt D. et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA. 2007;297:1985-1991.
6. Ginghina C, Bejan I, Ceck C. Modern risk stratification in coronary heart disease. J. MedLife. 2011;4(4):377-386.
7. Haji SA, Movahed A. Right ventricular infarction - diagnosis and treatment. Clin Cardiol. 2000;26(7):2023-2033.
8. Jensen CJ, Jochims M, Hunold P. et al. Right ventricular involvement in acute left ventricular myocardial infarction: prognostic implications of MRT findings. AJR. 2010;194:592-598.
9. Madsen JK, Nielsen TT, Grande P. et al. Revascularization compared to medical treatment in patients with silent vs. symptomatic residual ischemia after thrombolyzed myocardial infarction: the DANAMI study. Cardiology. 2007;108:243-251.
10. Montalescot G, Sechtem U, Achenbach S. et al. Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3004.
11. Shamir R, Eikelboom J. Madhu K. et al. Impact of right ventricular involvement on mortality a morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol. 2001;37:37-43.
12. Simpson SH, Eurich DT, Majumdar SR. et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;33:153-166.
13. Steg G, James S, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-2619.
14. Steg PG, Thuaire C, Himbert D. et al. DECOPI(DEsobstruction COronaire en PostInfarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J. 2004;25:2187-2194.
15. Velazquez E, Lee K, Deja M. et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. New Engl. J. Med. 2011;364:1607-1616.
16. Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541-2619.
17. Wong CK, White HD. Risk stratification of patients with right ventricular infarction: is there a need for a specific risk score? Eur Heart J. 2002;23:1642-1645.
18. Yusuf S, Flather M, Pogue J. et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without unitial ST elevation OASIS Registry Investigators. Lancet. 2000;152:507-514.

Хірургічне лікування супутньої патології при коригованій транспозиції магістральних судин

 О.Є. Рєпін, Л.С. Манюк, В.І. Корча, Є.К. Кептанару, О.Є. Малига, Є.І. Вирлан, І.В. Куку 

Література

1. Bache RJ, Vrobel TR. Effects of exercise on blood flow in the hypertrophied heart. J Am Coll Cardiol. 1978;44:1029.
2. Dobson R, Danton M, Nicola W, Hamish W. The natural and unnatural history of the systemic right ventricle in adult survivors. J Thorac Cardiovascular Surgery. 2013;145, Issue 6. Р. 1493-1503.
3. Graham TPJr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255-261.
4. Hauser M, Bengel F.M, Hager A, et al. Impaired myocardial blood flow and coronary flow reserve of the anatomical right systemic ventricle in patients with congenitally corrected transposition of the great arteries. Heart. 2003;89:1231-1235.
5. Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve disease in patients with congenitally corrected transposition of the great arteries. Circulation. 1998;98:997-1005.
6. Scherptong R, Vliegen H, Winter M. Tricuspid valve surgery in adults with a dysfunctional systemic right ventricle repair or replace? Circulation. 2009;119:1467-1472.
7. Shinbane J, Shriki J, Hindoyan A, et al. Unoperated congenitally corrected transposition of the great arteries, nonrestrictive ventricular septal defect,and pulmonary stenosis in middle adulthood: do multiple wrongs make a right? World J. Pediatric and Congenital Heart Surgery. 2012;3:123.
8. Tay E, Frogoudaki A, Inuzuka R, et al. Exercise intolerance in patients with congenitally corrected transposition of the great arteries relates to right ventricular filling pressure. Intern J Cardiology. 2011;147(2):219-223.
9. Winlaw DS, McGuirk SP, Balmer C, et al. Intention-to-treat analysis of pulmonary artery banding in conditions with a morphological right ventricle in the systemic circulation with a view to anatomic biventricular repair. Circulation. 2005;111:405-411.

Ехокардіографічна діагностика механічних ускладнень інфаркту міокарда

Н.Д. Орищин 

Література

1. Arnaoutakis GJ, Zhao Y, George TJ, et al. Surgical repair of ventricular septal defect after myocardial infarction: outcomes from the Society of Thoracic Surgeons National Database. Ann. Thrac. Surg. 2012;94(2):436-443.
2. Attia R, Blauth C. Which patients might be suitable for a septal occluder device closure of postinfarction ventricular septal rupture rather than immediate surgery?. Interact. Cardiovasc. Thorac. Surg. 2010;11:626-629.
3. Barbour DJ, Roberts WC. Rupture of a left ventricular papillary muscle during acute myocardial infarction: analysis of 22 necropsy patients. J. Am. Coll. Cardiol. 1986;8:558-565.
4. Birnbaum Y, Fishbein MC, Blanche C, et al. Ventricular septal rupture after acute myocardial infarction. New Engl. J. Med. 2002;347:1426-1432.
5. Bouma W, Wijdh-den Hamer IJ, Klinkenberg TJ, et al. Mitral valve repair for post-myocardial infarction papillary muscle rupture. Eur. J. Cardiothorac. Surg. 2013;44:1063-1009.
6. Bouma W, Wijdh-den Hamer IJ, Koene BM, et al. Predictors of in-hospital mortality after mitral valve surgery for post-myocardial infarction papillary muscle rupture. J. Cardiothorac. Surg. 2014;9:171.
7. Brown SL, Gropler RJ, Harris KR. Distinguishing left ventricular aneurysm from pseudoaneurysm. Chest. 1997;111:1403-1409.
8. Chen Q, Darlymple-Hay MJ, Alexiou C, et al. Mitral valve surgery for acute papillary muscle rupture following myocardial infarction. J. Heart Valve Dis. 2002;11:27-31.
9. Costache VS, Chavanon O, Bouvaist H, et al. Early Amplatzer occluder closure of a postinfarct ventricular septal defect as a bridge to surgical procedure. Interact. Cardiovasc. Thorac. Surg. 2007;6:503-504.
10. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation. 2000;101:27-32.
11. David TE, Dale L, Sun Z. Postinfarction ventricular septal rupture: repair by endocardial patch with infarct exclusion. Thorac. Cardiovasc. Surg. 1995;110:1315-1322.
12. Eren E, Bozbuga N, Toker M, et al. Surgical Treatment of Post-Infarction Left Ventricular Pseudoaneurysm. Tex. Heart Inst J. 2007;34(1):47-51.
13. Figueras J, Cortadellas J, Soler-Soler J. Comparison of ventricular septal and left ventricular free wall rupture in acute myocardial infarction. Am. J. Cardiol. 1998;81:495-497.
14. Fortin DF, Sheikh KH, Kisslo J. The utility of echocardiography in the diagnostic strategy of postinfarction ventricular septal rupture: a comparison of two-dimensional echocardiography versus Doppler color flow imaging. Am Heart J. 1991;121:25-32.
15. Frances C, Romero A, Grady D. Left ventricular pseudoaneurysm. J Am Coll Cardiol. 1998;32:557-561.
16. French JK, Hellkamp AS, Armstrong PW, et al. Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol. 2010;105:59-63.
17. Galve E, Garcia-Del-Castillo H, Evangelista A, et al. Pericardial effusion in the course of myocardial infarction: incidence, natural history, and clinical relevance. Circulation. 1986;73:294-299.
18. Gueret P, Khalife K, Jobic Y, et al. Study Investigators. Echocardiographic assessment of the incidence of mechanical complications during the early phase of myocardial infarction in the reperfusion era: a French multicentre prospective registry. Arch Cardiovasc Dis. 2008;101:41-47.
19. Jones M, Kapadia S. R, Smedira N.G, et al. Ventricular septal rupture complicating acute myocardial infarction: a contemporary review. Eur Heart J. 2014;35:2060-2068.
20. Holmes DR, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995;26:668-674.
21. Helmy TA, Nicholson WJ, Lick S, Uretsky BF. Contained myocardial rupture: a variant linking complete and ncomplete rupture. Heart. 2005;91(2):e13.
22. Kishon Y, Oh JK, Schaff HV, et al. Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow-up of 22 patients. Mayo Clin Proc. 1992;67:1023-1030.
23. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol. 1992;70:147-151.
24. López-Sendón J, González A, López de Sá E, et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol. 1992;19:1145-1153.
25. Lopez-Sendon J, Gurfinkel EP, Lopez de Sa E, et al. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010;31:1449-1456.
26. Lorusso R, Gelsomino S, De Cicco G, et al. Mitral valve surgery in emergency for severe acute regurgitation: analysis of postoperative results from a multicentre study. Eur J Cardiothorac Surg. 2008;33:573-582
27. Maltais S, Ibrahim R, Basmadjian AJ, et al. Postinfarction ventricular septal defects: towards a new treatment algorithm? Ann Thorac Surg. 2009;87:687-692.
28. Merce J, Sagrista-Aauleda J, Permanyer-Miralda G, et al. Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade. Am Heart J. 1999;138:759-764.
29. Moreno R, Gordillo E, Zamorano J, et al. Long term outcome of patients with postinfarction left ventricular pseudoaneurysm. Heart. 2003;89:1144-1146.
30. Obarski TP, Rogers РJ, Debaets DL, et al. Assessment of postinfarction ventricular septal ruptures by transesophageal Doppler echocardiography. J Am Soc Echocardiogr. 1995;8:728-734.
31. Perdigao C, Andrade A, Ribiero C. Cardiac rupture in acute myocardial infarction: various clinico-anatomical types in 42 recent cases observed over a period of 30 months. Arch Mal Coeur Vaiss. 1987;80:336-344.
32. Poulsen SH, Praestholm M, Munk K, et al. Ventricular septal rupture complicating acute myocardial infarction: clinical characteristics and contemporary outcome. Ann Thorac Surg. 2008;85:1591-1596.
33. Pohjola-Sintonen S, Muller JE, Stone PH, et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the Multicenter Investigation of Limitation of Infarct Size. Am Heart J. 1989;117:809-818.
34. Pretre R, Linka A, Jenni R, Turina MI. Surgical treatment of acquired left ventricular pseudoaneurysms. Ann. Thorac. Surg. 2000;70:553-557.
35. Purcaro A, Costantini C, Ciampani N, et al. Diagnostic criteria and management of subacute ventricular free wall rupture complicating acute myocardial infarction. Am J Cardiol. 1997;80:397-405.
36. Ruhparwar A, Karck M, Kallenbach K, et al. Long-term results after surgical treatment of postinfarction ventricular septal rupture. Eur. J. Cardiothorac. Surg. 2015;47(4):720-724.
37. Russo A, Suri R.M, Grigioni F, et al. Clinical outcome after surgical correction of mitral regurgitation due to papillary muscle rupture. Circulation. 2008;118:1528-1534.
38. Serpytis P, Karvelyte N, Serpytis RA. Post-infarction ventricular septal defect: risk factors and early outcomes. Helelnic J. Cardiol. 2015;56(1):66-71.
39. Smyllie JH, Sutherland GR, Geuskens R, et al. Doppler color flow mapping in the diagnosis of ventricular septal rupture and acute mitral regurgitation after myocardial infarction. J Am Coll Cardiol. 1990;15:1449-1455.
40. Schroeter T, Lehmann S, Misfeld M, et al. Clinical outcome after mitral valve surgery due to ischemic papillary muscle rupture. Ann Thorac Surg. 2013;95:820-824.
41. Tanaka K, Sato N, Yasutake M, et al. Clinicopathological characteristics of 10 patients with rupture of both ventricular free wall and septum (double rupture) after acute myocardial infarction. J Nippon Med Sch. 2003;70(1):21-27.
42. Tavakoli R, Weber A, Vogt P, et al. Surgical management of acute mitral valve regurgitation due to post-infarction papillary muscle rupture. J Heart Valve Dis. 2002;11:20-25.
43. Terashima M, Fujiwara S, Yaginuma G.Y, et al. Outcome of percutaneous intrapericardial fibrin-glue injection therapy for left ventricular free wall rupture secondary to acute myocardial infarction. Am J Cardiol. 2008;101:419-421.
44. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Hould we use emergently revascularize Occluded Coronaries in cardiogenic shock? J Am Coll Cardiol. 2000;36:1104-1109.
45. Zoffoli, G, Battaglia, F, Venturini A, et al. A novel approach to ventricular rupture: clinical needs and surgical technique. Ann. Thorac. Surg. 2001;93:1002-1003.
46. Yeo TC, Malouf JF, Oh JF, Seward JB. Clinical profile and outcome in 52 patients with cardiac pseudoaneurysm. Ann. Intern. Med. 1998;128:299-305.

Видалення фіброеластоми аортального клапана з використанням малоінвазивного доступу

Б.М. Тодуров, М.Д. Глагола, Г.І. Дарвіш, О.Г. Біцадзе, А.В. Іванюк, Н.В. Шателен, О.С. Болгова,
С.І. Дорофеєва

Література

1. Ivanov AS, Baloyan GM, Rodionov MS. Papillary fibroelastoma of the heart. Kardiologiya i serdechno-sosudistaya khirurgiya [Cardiology and Cardiovascular Surgery]. 2009;4:91-94. (in Rus.).
2. Alawi A, Kassabian EB, Ashoush R, et al. Aortic valve papillary fibroelastoma. Cardiovasc Surg. 2002;10:65-67.
3. Alozie A, Prall F, Hendrikson C, et al. Embolization of multiple papillary fibroelastoma of the aortic valve as cause of a ST-segment elevation myocardial infarction. Eur J Echocardiogr. 2011;12:817.
4. Eckstein FS, Schafer HJ, Grote J, et al. Papillary fibroelastoma of the aortic valve presenting with myocardial infarction. Ann Thorac Surg. 1995;60:206-208.
5. Edwards FY, Hale D, Cohen A, et al. Primary cardiac valve tumors. Ann. Thorac. Surg. 1991;52:1127-1131.
6. Erdoes G, Stalder M, Basciani R, et al. An uncommon cause of coronary artery ostial obstruction: papillary fibroelastoma. Echocardiography. 2010;27:337-340.
7. Gilbert P, Bourgault C, Couture C, et al. Splenic infarction associated with a mobile aortic valve lesion: a case report and the review of the literature. Can J Cardiol. 2009;25:215-216.
8. Gowda R.M, Khan I.A, Nair C.K, et al. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003;146:404-410.
9. Grande A.M, Massetti M, Castiglione N, et al. Valve-sparing removal of aortic valve papillary fibroelastoma through ministernotomy. J Heart Valve Dis. 2007;16:206-208.        
10. Grandmougin D, Fayad G, Moukassa D, et al. Cardiac valve papillary fibroelastomas: clinical, histological and immunohistochemical studies and a physiopathogenic hypothesis. J. Heart Valve Dis. 2000;9:832-841.
11. Harling L, Athanasiou T, Ashrafian H, et al. Minimal access excision of aortic valve fibroelastoma: a case report and review of the literature. J. Cardiothorac. Surg. 2012;7:80-88.
12. Heath D, Best PV, Davis BT. Papilliferous tumours of the heart valves. Br. Heart J. 1961;23:20-24.
13. Hsu VM, Atluri P, Keane MG, et al. Minimally invasive aortic valve papillary fibroelastoma resection. Interact Cardiovasc Thorac Surg. 2006;5:779-781.
14. Je HG, Kim YS, Jung SH, et al. Resection of left ventricular papillary fibroelastoma through thoracoscopic-assisted minithoracotomy. Interact Cardiovasc Thorac Surg. 2008;7:320-321.
15. Kurup AN, Tazelaar HD, Edwards WD, et al. Iatrogenic cardiac papillary fibroelastoma: a study of 12 cases (1990 to 2000). Hum Pathol. 2002;33:1165-1169.
16. Mathur A, Airan B, Bhan A, et al. Non-myxomatous cardiac tumors: twenty-years experience. Indian Heart J. 2000;52:319-323.
17. Moreno-Cabral R. Mini T-sternotomy for cardiac operations. J Thorac Cardiovasc Surg. 1997;113:810-811.
18. Ngaage DL, Mullany CJ, Daly RC, et al. Surgical treatment of cardiac papillary fibroelastoma: a single center experience with eighty-eight patients. Ann Thorac Surg. 2005;80:1712-1718.
19. Okada K, Sueda T, Orihashi K, et al. Cardiac papillary fibroelastoma on the pulmonary valve: a rare cardiac tumor. Ann Thorac Surg. 2001;71:1677-1679.
20. Pello SJ, Ashkenazi A. Spinal cord infarction in a woman with cardiac fibroelastoma. Neurologist. 2011;17:47-48.
21. Raeburn C. Papillary fibro-elastic hamartomas of the heart valves. J Pathol Bacteriol. 1953;65:371-373.
22. Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77:107.
23. Rubin MA, Snell JA, Tazelaar HD, et al. Cardiac papillary fibroelastoma: an immunohistochemical investigation and unusual clinical manifestation. Mod. Pathol. 1995;8:402-407.
24. Ryan PE, Obeid A, Parker FB. Primary cardiac valve tumors. J Heart Valve Dis. 1995;4:222-226.
25. Salyer WR, Page DL, Hutchins GM. The development of cardiac myxomas and papillary endocardial lesions from mural thrombus. Am Heart J. 1975;89:4-17.
26. Shahian DM, Labib SB, Chang G. Cardiac papillary fibroelastoma. Ann Thorac Surg. 1995;59:538-541.
27. Sun JP, Asher CR, Yang XS, et al. Clinical and echocardiographic characteristics of papillary fibroelastomas: A retrospective and prospective study in 162 patients. Circulation. 2001;103:2687-2693.
28. Wang WL, Cai KC, Zeng WS, et al. Experience in using three different minimally invasive approaches in cardiac operations. Med. Sci. Monit. 2003;9:109-113.
29. Yamada T, Ochiai R, Takeda J, et al. Comparison of early postoperative quality of life in minimally invasive versus conventional valve surgery. J. Anesth. 2003;17:171-176.

Лікування аритмогенної кардіоміопатії (дисплазії) правого шлуночка

М.Т. Ватутін, Г.С. Смирнова, Є.В. Єщенко, Г.Е. Дегтярьова, В.С. Колесніков, Ю.П. Гриценко

Джерело

Corrado D, Wichter T, Link MS, et al. Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. An International Task Force Consensus Statement. Circulation. 2015;132:441-453.

Хірургічна та інтервенційна корекція мітральної регургітації: позиційний документ Робочих груп з питань кардіохірургії та клапанних захворювань серця  Європейського товариства кардіологів

M. De Bonis, N. Al-Attar, M. Antunes, M. Borger, F. Casselman, V. Falk, T. Folliguet, B. Iung, P. Lancellotti,
S. Lentini, F. Maisano, D. Messika-Zeitoun, C. Muneretto, P. Pibarot, L. Pierard, P. Punjabi, R. Rosenhek,
P. Suwalski, A. Vahanian, O. Wendler, B. Prendergast

Література

1. Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. New Engl J Med. 2014;370:23-32.
2. Akins CW, Miller DC, Turina MI, et al. Councils of the American Association for Thoracic Surgery; Society of Thoracic Surgeons; European Assoication for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 2008;135:732-738.
3. Alozie A, Westphal B, Kische S, et al. Surgical revision after percutaneous mitral valve repair by edge-to-edge device: when the strategy fails in the highest risk surgical population. Eur J Cardiothorac Surg. 2014;46:55-60.
4. Anyanwu AC, Bridgewater B, Adams DH. The lottery of mitral valve repair surgery. Heart. 2010;96:1964-1967.
5. Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012;14:1050-1055.
6. Bolling SF, Deeb GM, Brunsting LA, Bach DS. Early outcome of mitral valve reconstruction in patients with end-stage cardiomyopathy. J Thorac Cardiovasc Surg. 1995;4:676-683.
7. Borger MA, Alam A, Murphy PM, David TE. Ischemic mitral regurgitation: repair, replace or revisit? Ann Thorac Surg. 2006;81:1153-1161.
8. Borger MA, Murphy PM, Alam A, et al. Initial results of the chordal-cutting operation for ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2007;133:1483-1492.
9. Braunberger E, Deloche A, Berrebi A, et al. Very long-term results (more than 20 years) of valve repair with carpentier’s techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104 (12):I8-11.
10. Castillo JG, Anyanwu AC, Fuster V, Adams D.H. A near 100 % repair rate for mitral valve prolapse is achievable in a reference center: implications for future guidelines. J Thorac Cardiovasc Surg. 2012;144:308-312.
11. Cheung A, Webb J, Verheye S, et al. Shortterm results of transapical transcatheter mitral valve implantation for mitral regurgitation. J Am Coll Cardiol. 2014;64:1814-1819.
12. Chiam PT, Ruiz CE. Percutaneous transcatheter mitral valve repair: a classification of the technology. JACC Cardiovasc. Interv. 2011;4:1-13.
13. Ciarka A, Braun J, Delgado V, et al. Predictors of mitral regurgitation recurrence in patients with heart failure undergoing mitral valve annuloplasty. Am J Cardiol. 2010;106:395-401.
14. David TE, Armstrong S, McCrindle BW, Manlhiot C. Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation. 2013;127:1485-1492.
15. De Bonis M, Lapenna E, Maisano F, et al. Long-term results (≤ 18 years) of the edge-to-edge mitral valve repair without annuloplasty in degenerative mitral regurgitation: implications for the percutaneous approach. Circulation. 2014;130 (11 Suppl. 1):S19-S24.
16. De Bonis M, Lorusso R, Lapenna E, et al. Similar long-term results of mitral valve repair for anterior compared with posterior leaflet prolapse. J Thorac Cardiovasc Surg. 2006;131:364-368.
17. Di Bardino DJ, El Bardissi AW, McClure RS, et al. Four decades of experience with mitral valve repair: analysis of differential indications, technical evolution, and long-term outcome. J Thorac Cardiovasc Surg. 2010;139:76-83.
18. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. New Engl. J. Med. 2011;364:1395-1406.
19. Franzen O, Baldus S, Rudolph V, et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J. 2010;31:1373-1381.
20. Frerker C, Schafer U, Schewel D, et al. Percutaneous approaches for mitral valve interventions - a real alternative technique for standard cardiac surgery? Herz. 2009;34:444-450.
21. Geidel S, Schmoeckel M. Impact of failed mitral clipping on subsequent mitral valve operations. Ann Thorac Surg. 2014;97:56-63.
22. Gillinov AM, Blackstone EH, Nowicki ER, et al. Valve repair versus valve replacement for degenerative mitral valve disease. J Thorac Cardiovasc Surg. 2008;135:885-893.
23. Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64:172-181.
24. Grasso C, Capodanno D, Scandura S, et al. One- and twelve-month safety and efficacy outcomes of patients undergoing edge-to-edge percutaneous mitral valve repair (from the GRASP Registry). Am J Cardiol. 2013;111:1482-1487.
25. Grayburn PA, Foster E, Sangli C, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128:1667-1674.
26. Heikkinen J, Biancari F, Satta J, et al. Quality of life after mitral valve repair. J. Heart Valve Dis. 2005;14:722-726.
27. Hvass U, Joudinaud T. The papillary muscle sling for ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2010;139:418-423.
28. Iung B, Baron G, Butchardt EG, et al. A prospective survey of patients with valvular heart disease in Europe: the EuroHeart survey on valvular heart disease. Eur Heart J. 2003;24:1231-1243.
29. Jouan J, Berrebi A, Chauvaud S, et al. Mitral valve reconstruction in Barlow disease: long-term echographic results and implications for surgical management. J Thorac Cardiovasc Surg. 2012;143 (4 Suppl.):S17-S20.
30. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012;33:2403-2418.
31. Langer F, Kunihara T, Hell K, et al. RING+STRING: successful repair technique for ischemic mitral regurgitation with severe leaflet tethering. Circulation. 2009;120:S85-S91.
32. Lee AP, Acker M, Kubo SH, et al. Mechanisms of recurrent functional mitral regurgitation after mitral valve repair in nonischemic dilated cardiomyopathy: importance of distal anterior leaflet tethering. Circulation. 2009;119:2606-2614.
33. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011;32:205-217.
34. Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014;64:182-192.
35. Lorusso R, Gelsomino S, Vizzardi E. et al, ISTIMIR Investigators. Mitral valve repair or replacement for ischemic mitral regurgitation? The Italian Study on the Treatment of Ischemic Mitral Regurgitation (ISTIMIR). J Thorac Cardiovasc Surg. 2013;145:128-139.
36. Lubos E, Schluter M, Vettorazzi E, et al. MitraClip therapy in surgical high-risk patients: identification of echocardiographic variables affecting acute procedural outcome. JACC Cardiovasc Interv. 2014;7:394-402.
37. Magne J, Girerd N, Senechal M, et al. Mitral repair versus replacement for ischemic mitral regurgitation: comparison of short-term and long-term survival. Circulation. 2009;120:S104-S111.
38. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052-1061.
39. Maisano F, Vanermen H, Seeburger J, et al. Direct access transcatheter mitral annuloplasty with a sutureless and adjustable device: preclinical experience. Eur J Cardiothorac Surg. 2012;42:524-529.
40. Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013;62:317-328.
41. McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2004. 128:916-924.
42. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
43. Mihaljevic T, Lam B.K, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. 2007;49:2191-2201.
44. Minha S, Torguson R, Waksman R. Overview of the 2013 Food and Drug Administration Circulatory System Devices Panel meeting on the MitraClip Delivery System. Circulation. 2013;128:864-868.
45. Montant P, Chenot F, Robert A, et al. Long-term survival in asymptomatic patients with severe degenerative mitral regurgitation: a propensity scorebased comparison between an early surgical strategy and a conservative treatment approach. J Thorac Cardiovasc Surg. 2009;138:1339-1348.
46. Murashita T, Okada Y, Fujiwara H, et al. Mechanism of and risk factors for reoperation after mitral valve repair for degenerative mitral regurgitation. Circ J. 2013;77:2050-2055.
47. Nkomo VT, Gardin JM, Skelton TN. Burden of valvular heart disease: a populationbased study. Lancet. 2006;368:1005-1011.
48. Puls M, Tichelbacker T, Bleckmann A, et al. Failure of acute procedural success predicts adverse outcome after percutaneous edge-to-edge mitral valve repair with MitraClip. EuroIntervention. 2014;9:1407-1417.
49. Reichenspurner H, Schillinger W, Baldus S, et al. Clinical outcomes through 12 months in patients with degenerative mitral regurgitation treated with the MitraClip(R) device in the ACCESS-EUrope Phase I trial. Eur J Cardiothorac Surg. 2013; 44:280-e288.
50. Rosenhek R, Iung B, Tornos P. et al, ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. Eur Heart J. 2012;33:822-828.
51. Rucinskas K, Janusauskas V, Zakarkaite D, et al. Off-pump transapical implantation of artificial chordae to correct mitral regurgitation: early results of a single-center experience. J Thorac Cardiovasc Surg. 2014;147:95-99.
52. Rudolph V, Knap M, Franzen O, et al. Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery. J Am Coll Cardiol. 2011;58:2190-2195.
53. Salvador L, Mirone S, Bianchini R, et al. A 20-year experience with mitral valve repair with artificia chordae in 608 patients. J Thorac Cardiovasc Surg. 2008;135:1280-1287.
54. Schillinger W, Hunlich M, Baldus S, et al. Acute outcomes after MitraClip therapy in highly aged patients: results from the German TRAnscatheter Mitral valve Interventions (TRAMI) Registry. EuroIntervention. 2013;9:84-90.
55. Spoor MT, Geltz A, Bolling SF. Flexible versus nonflexible mitral valve rings for congestive heart failure. Circulation. 2006;114(I):I67-I71.
56. Taramasso M, Maisano F, Latib A, et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention. 2014;10:746-752.
57. Vahanian A, Alfieri O, Andreotti F. et al, Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451-2496.
58. Van den Branden BJ, Swaans MJ, Post MC, et al. Percutaneous edge-to-edge mitral valve repair in high-surgical-risk patients: do we hit the target?. JACC Cardiovasc Interv. 2012;5:105-111.
59. Vassileva CM, Mishkel G, McNeely C, et al. Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation. 2013;127:1870-1876.
60. Whitlow PL, Feldman T, Pedersen WR, et al. EVEREST II Investigators. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012;59:130-139.
61. Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. 2005;45:381-387.
62. Yun KL, Miller DC. Mitral valve repair versus replacement. Cardiol Clin. 1991;9:315-327.